Was Amy Bachrodt’s Maze Therapeutics share sale pre-planned under Rule 10b5-1?

Yes. A footnote states the reported sale transactions were effected under a Rule 10b5-1 trading plan she adopted on September 29, 2025. Such plans allow pre-scheduled trading, providing a structured approach to selling shares over time under predetermined conditions.

Maze Therapeutics (MAZE) SVP logs option, RSU grants and sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics SVP, Finance Amy Bachrodt reported multiple equity transactions on March 2, 2026. She exercised a stock option for 5,000 shares of common stock at $10.42 per share and received a new stock option grant for 32,000 shares plus 16,000 restricted stock units, all held directly.

On the same date, she sold 1,300 shares of common stock at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694, in open‑market transactions under a Rule 10b5‑1 trading plan adopted on September 29, 2025. The footnotes note price ranges for these weighted averages and describe monthly vesting for the options and annual vesting tranches for the RSUs, subject to continued service.

Insider Trade Summary

Net Seller: 5,000 shares ($226,011)

Net Sell 6 txns

Insider Bachrodt Amy

Role SVP, Finance

Sold 5,000 shs ($226K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	32,000	$0.00	--
Grant/Award	Restricted Stock Units	16,000	$0.00	--
Exercise	Common Stock	5,000	$10.42	$52K
Sale	Common Stock	1,300	$44.4414	$58K
Sale	Common Stock	3,700	$45.4694	$168K

Holdings After Transaction: Stock Option (Right to Buy) — 36,333 shares (Direct); Restricted Stock Units — 16,000 shares (Direct); Common Stock — 17,965 shares (Direct)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 12:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bachrodt Amy

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		M⁽¹⁾		5,000	A	$10.42	17,965	D
Common Stock	03/02/2026		S⁽¹⁾		1,300	D	$44.4414⁽²⁾	16,665	D
Common Stock	03/02/2026		S⁽¹⁾		3,700	D	$45.4694⁽³⁾	12,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$10.42	03/02/2026		M⁽¹⁾			5,000	⁽⁴⁾	12/08/2034	Common Stock	5,000	$0	36,333	D
Stock Option (Right to Buy)	$45.61	03/02/2026		A		32,000		⁽⁵⁾	03/01/2036	Common Stock	32,000	$0	32,000	D
Restricted Stock Units	⁽⁶⁾	03/02/2026		A		16,000		⁽⁷⁾	⁽⁸⁾	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive.

4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

5. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

7. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

8. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Maze Therapeutics (MAZE) SVP Amy Bachrodt report on this Form 4?

Amy Bachrodt reported a mix of equity transactions, including option exercises, new option and RSU grants, and open-market share sales. All transactions occurred on March 2, 2026, and relate to Maze Therapeutics common stock and derivative equity awards held directly.

How many Maze Therapeutics shares did Amy Bachrodt sell and at what prices?

She sold 1,300 shares at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694. Footnotes explain these are weighted averages across multiple trades within specified intraday price ranges for each reported transaction.

What equity awards did Amy Bachrodt receive from Maze Therapeutics on March 2, 2026?

She received a stock option grant for 32,000 shares and a restricted stock unit grant for 16,000 units. The option vests monthly over 48 months starting April 1, 2026, while the RSUs vest in four equal annual tranches beginning March 1, 2027, subject to continued service.

How do Amy Bachrodt’s Maze Therapeutics options and RSUs vest over time?

One option referenced vests in monthly installments of 1/48 of the total award starting January 1, 2025. The new option vests monthly over 48 months from April 1, 2026. The RSUs vest 25% annually, beginning March 1, 2027, conditioned on continued service.

What does each restricted stock unit represent in this Maze Therapeutics Form 4?

Each restricted stock unit represents a contingent right to receive one share of Maze Therapeutics common stock upon settlement. The footnotes clarify these RSUs do not expire but will either vest on scheduled dates or be cancelled if vesting conditions, including continued service, are not met.